In the present study, we have evaluated the apoptotic effect of soluble human MHC class I (sHLA-I) antigens on CD8 ⍣ T lymphocytes. sHLA-I antigens and β 2 -microglobulin-free HLA class I heavy chains, isolated from serum, induced apoptosis on phytohemagglutinin-activated CD8 ⍣ T lymphocytes in autologous and allogeneic combinations. The extent of CD8 ⍣ T cell apoptosis depends on the degree of activation, time of incubation with sHLA-I antigens and amount of sHLA-I antigens added to the cultures. Apoptosis is induced by the interaction of Fas (CD95) ⍣ cells with soluble Fas ligand which is released following binding of sHLA-I antigens to CD8 molecules. These results suggest that sHLA-I antigens may regulate immune responses by inducing apoptosis in activated CD8 ⍣ T cells.
Introduction
It has been known for some time that besides being recently, sHLA-I antigens have been found to be immunogenic in allogeneic combinations (11) . Lastly, sHLA-I antigens have expressed on nucleated cells (1) immunologically functional been shown to inhibit the cytotoxicity of alloreactive cytotoxic β 2 -microglobulin (β 2 m)-associated HLA class I heavy chains T lymphocytes (12-15) and to induce apoptosis of primary (sHLA-I) are present in serum (2-4). More recently the alloreactive CD8 ϩ T cells through selective stimulation of the presence of β 2 m-free HLA class I heavy chains (free heavy TCR (16) . chains) in serum has also been described (5,6). The level of Whether sHLA-I antigens and the increase in their serum β 2 m-associated as well as -free heavy chains is significantly level in patients with activation of their immune system play increased in serum of patients with an activation of their a role in the regulation of the immune response in autologous immune system such as those suffering from an acute rejection combinations is not known. In the present study, we have episode following organ allografts, acute graft versus host addressed these questions by investigating the interaction of disease following bone marrow transplantation, autoimmune sHLA-I antigens and free heavy chains with T cells, and the diseases or viral infections (7 and personal data). Because of functional consequences of these interactions. the statistically significant association with clinical parameters, the level of sHLA-I antigens has been suggested to represent a useful marker to predict the evolution of HIV infections and Methods to monitor the clinical course of allografts (8,9). The potential involvement of sHLA-I antigens in the outcome of allografts mAb and conventional antisera is suggested by at least three lines of evidence. The early findings by van Rood and his collaborators that skin allograft
The anti-β 2 m-associated HLA class I heavy chains α 3 domain survival is prolonged following plasma administration implies mAb W6/32, the anti-β 2 m-associated and anti-β 2 m-free HLA class I heavy chains α 3 domain mAb TP25.99, the anti-HLAthat sHLA-I antigens may have a tolerogenic effect (10) . More A3 α 1 domain mAb LGIII-220.6, the anti-HLA-A3 α 2 domain reducing/denaturing conditions followed by silver staining or immunoblotting with 125 I-labeled anti-HLA class I mAb mAb TP11, the anti-β 2 m-free HLA class I heavy chains mAb HC-10, the anti-β 2 m mAb NAMB-1, the anti-HLA class II mAb TP25.99, as described (25) . Soluble HLA class II antigens were purified from HUT 78 LGII-612.14, the anti-ICAM-1 mAb VF27-516.1, and the antihuman Fas ligand (FasL) neutralizing mAb 4H9 were cells by affinity chromatography on anti-HLA class II mAb LGII-612.14, as described (28) . Soluble CD8 antigen was developed and purified as described (17-24 and unpublished results). The anti-CD3 mAb OKT3, the anti-CD4 mAb OKT4 purchased from T Cell Diagnostics (Cambridge, MA). Soluble human recombinant FasL was purchased from Alexis (Lä uand the anti-CD8 α chain mAb OKT8 were purchased from Ortho (Milan, Italy). The anti-human TCR mAb TCR-1α/β was felfingen, Switzerland). purchased from Becton Dickinson (San Jose, CA). The antiImmunoassays CD8 β chain mAb CD8β and the anti-human Fas mAb UB2 were purchased from Immunotech (Marseilles, France). The
The double-determinant immune assay (DDIA) was performed as described (29) utilizing anti-HLA class I mAb W6/32 anti-human Fas mAb CH11 and ZB4 were purchased from Kamiya (Thousand Oaks, CA). The mAb NOK-1 and NOK-2 and biotinylated anti-β 2 m mAb NAMB-1 to measure sHLA-I antigens, anti-HLA class I heavy chains mAb TP25.99 and to different epitopes of human soluble FasL were purchased from PharMingen (San Diego, CA). mAb were labeled with biotinylated anti-free heavy chains mAb HC-10 to measure free heavy chains, and anti-sFasL mAb NOK-2 and 125 I utilizing the chloramine T method (25) or conjugated to biotin (Pierce, Rockford, IL) according to the manufacturer's biotinylated anti-sFasL mAb NOK-1 to measure sFasL. The binding of sHLA-I molecules to CD8 was assessed as follows. procedure. FITC-conjugated goat anti-mouse Ig antibodies (GAM-FITC) were purchased from Coulter (Hialeah, FL).
Polyvinylchloride 96-well plates (Becton Dickinson, Oxnard, CA) were coated overnight at 4°C with anti-CD8 β chain mAb Annexin-V-biotin and streptavidin-R-phycoerythrin were purchased from Boehringer Mannheim (Monza, Italy).
CD8β (15 µg/ml) in bicarbonate buffer (0.01 M, pH 9.5), washed with PBS/0.2% Tween 20 and blocked with PBS/5% Cells BSA. Soluble CD8 molecules (500 U/ml), biotinylated or nonbiotinylated anti-CD8 α chain mAb OKT8 (5 µg/ml), sHLA-I Human peripheral blood mononuclear cells were obtained from healthy donors as described (26) . CD8 ϩ T and CD4 ϩ T molecules (4 µg/ml) and biotinylated anti-β 2 m mAb NAMB-1 (5 µg/ml) were sequentially added in 100 µl volume to cells were purified by negative selection on anti-CD4 and anti-CD8 mAb-coated magnetic beads (Dynal, Oslo, Norway) microtiter plates for 1 h at 37°C. After washings with PBS/ 0.2% Tween 20, streptavidin-HPC (Pierce, Rockford, IL) was respectively. Purity of CD4 ϩ and CD8 ϩ T cell preparations as assessed by flow cytometric analysis was at least 90%.
added for 1 h at 37°C and the reaction was developed for 15 min at room temperature in the dark with o-phenylene-CD8 ϩ and CD4 ϩ T cells were activated with phytohemagglutinin (PHA) (10 µg/ml) in RPMI 1640 medium (Gibco/ diamine (40 µg/ml) in phosphate citrate buffer (pH 5.0) supplemented with 0.04% (v/v) H 2 O 2 30%. The optical density BRL, Gaithersburg, MD) supplemented with 10% FBS (Gibco/BRL) for up to 72 h at 37°C in a 5% CO 2 atmosphere.
(OD) was read with a spectrophotometer at 490 nm against reagent blank (PBS/5% BSA). Results were expressed as Cultured human B lymphoid cells HUT 78 and human T lymphoid cells Jurkat (CD2 ϩ , CD3 ϩ , CD8 -, CD95 ϩ , HLA mean Ϯ SD of triplicate wells. Indirect immunofluorescence (IIF) was performed by class I -) were grown in RPMI 1640/FBS 10% medium at 37°C in a 5% CO 2 atmosphere.
incubating 5ϫ10 5 cells sequentially with mAb and with GAM-FITC. Each incubation was for 30 min at 4°C. Following three Antigen preparations washings, cells were analyzed on an Epics Elite flow cytometer (Coulter). Results are expressed as fluorescence intensity. sHLA-I molecules were purified from serum of healthy subjects by sequential precipitation with ammonium sulfate (60, 40 Induction and detection of apoptosis and 20%). Supernatant of the 20% fraction was sequentially applied in a low/medium-pressure chromatography system PHA-activated T cells (10 6 /ml) or Jurkat cells that are susceptible to FasL-mediated apoptosis were washed and (BioLogic; BioRad, Milan, Italy) to strong anionic ion exchange Sourse 30 Q, strong cationic ion exchange Sourse 30 S and then cultured in 96-well U-bottomed plates (Becton Dickinson) with RPMI 1640/ 10% FBS culture medium alone or with gel filtration HiPrep Sephacryl S-200 columns (Pharmacia, Uppsala, Sweden), and then purified by affinity chromatoculture medium containing apoptosis inducing stimuli for up to 72 h at 37°C in a 5% CO 2 atmosphere. After 48 h of graphy on anti-HLA class I mAb W6/32 (10 mg/ml) coupled to cyanogen bromide-activated Sepharose 4B (Pharmacia).
incubation, 5ϫ10 5 cells were washed and early apoptotic events were evaluated by Annexin-V labeling method accordFree heavy chains were eluted from sHLA-I molecules with acetic acid (0.1 N, pH 2) for 5 min at room temperature ing to the manufacturer's protocol. Viable apoptotic cells were differentiated from dead cells by flow cytometry after (27) . The solution was then neutralized with 1 M Tris buffer, pH 11.0 (Sigma, Milan, Italy). Following four sequential 4 h propidium iodide (PI) staining of non-permeabilized cells. At the end of incubation, 1ϫ10 6 cells were washed and analyzed incubations at room temperature with anti-β 2 m mAb NAMB-1 coupled to cyanogen bromide-activated Sepharose 4B to on a Epics Elite flow cytometer (Coulter) after permeabilization and PI staining, by DNA gel electrophoresis and by electron remove free β 2 m, the antigen preparation was dialyzed against PBS (pH 7.4) overnight at 4°C. The purity of sHLA-I molecules microscopy utilizing a Siemens Elmiskop 101 transmission electron microscope (Siemens, Iselin, NJ), as described and free heavy chains preparations was analyzed by onedimensional PAGE under non-reducing/non-denaturing or (30) (31) (32) (Fig. 1, lane  3) . Similar results were obtained when the free heavy chains isolated from the HLA class I molecular complex by dissociation of β 2 m were analyzed (Fig. 1, lane 4) . The free heavy chains reacted in the DDIA performed with mAb TP25.99 and mAb HC-10 which recognize determinants expressed on free heavy chains but did not react with anti-β 2 m mAb NAMB-1 (data not shown).
Induction by sHLA-I molecules of apoptosis in PHA-activated CD8 ϩ T lymphocytes
Incubation for up to 72 h of sHLA-I molecules with autologous when PHA-activated CD8 ϩ T cells were incubated for 72 h with allogeneic sHLA-I molecules or with free heavy chains (Fig. 2B) . The apoptotic effect of sHLA-I molecules is specific for the CD8 ϩ T cell subset since PHA-activated CD4 ϩ T lymphoIsolation of RNA and reverse transcription cytes did not undergo apoptosis when cultured with sHLA-I Total RNA was isolated from cell pellets by using the RNAzol molecules as indicated by DNA gel electrophoresis (Fig. 2C , B (Biotecx, Houston, TX) method according to the manufaclane 4) and by PI staining (data not shown). The number of turer's protocol. cDNA (corresponding to 2 µg of RNA) was CD8 ϩ T cells undergoing apoptosis is influenced by the extent synthesized from oligo(dT)-primed RNA in 20 µl reverse of PHA activation of T cells, by the incubation time with sHLA-I transcriptase buffer and 200 U MMLV reverse transcriptase molecules and by the concentration of sHLA-I molecules (Perkin-Elmer Cetus, Emeryville, CA) incubated at 42°C for ( Fig. 3A and B) . The apoptosis-inducing activity of sHLA-I 45 min and at 52°C for 45 min.
molecules is higher than that of well-known apoptotic stimuli such as methylprednisolone, anti-CD3 mAb and anti-TCR mAb PCR amplification (Fig. 3C ). Soluble HLA class II antigens, anti-HLA class I mAb, The PCR mixture contained 2 µl of cDNA, 2.5 mM MgCl 2 , anti-CD8 mAb and anti-ICAM-1 mAb did not induce apoptosis 2 mM dNTP, 50 µM 5Ј and 3Ј oligonucleotide primers, and in PHA-activated CD8 ϩ T cells (Fig. 3C) . The apoptotic effect 2.5 U Amply Taq Gold Polymerase (Perkin-Elmer Cetus). The of sHLA-I antigens was inhibited by their preincubation with PCR mixture was amplified by 35 cycles of denaturation at an anti-HLA class I α 3 domain mAb and with soluble CD8 94°C for 1 min, annealing at 60°C for 30 s and extension at molecules as well as by preincubation of target cells with an 72°C for 30 s in 0.2 ml thin-walled tubes in a total volume anti-CD8 α chain mAb (Table 1) . Apoptosis was unaffected by of 50 µl. Primer sequences used were: β-actin 5Ј-GTGGGGanti-CD8 mAb if added to cells preincubated for 1 h with sHLA-CGCCCCAGGCACCA, β-actin 3Ј-CTCCTTAATGTCACGCA-I molecules (data not shown). These results suggest that CGATTTC (548 bp fragment); Fas 5Ј-ATGCTGGGCATCTapoptosis is triggered by the interaction between the sHLA-I GGACCCT, Fas 3Ј-GCCATGTCCTTCATCACACAA (335 bp α 3 domain and CD8 α chain. This possibility is also supported fragment); and FasL 5Ј-CAAGTCCAACTCAAGGTCCATGCC, by the binding of sHLA-I antigens to CD8 molecules which have FasL 3Ј-CAGAGAGAGCTCAGATACGTTGAC (350 bp fragbeen immobilized to a solid support by an anti-CD8 β chain ment) (33, 34) . PCR products were size-fractionated by mAb and by the blocking of this binding by an anti-CD8 α chain agarose electrophoresis and normalized according to the mAb (Table 2) . amount of β-actin detected in the same mRNA sample.
We also investigated whether a sHLA-I-TCR interaction might contribute to the apoptotic effect of sHLA-I molecules. To this end PHA-activated CD8 ϩ T cells were preincubated with an Results anti-CD8 α chain mAb before adding sHLA-I molecules. In Immunochemical profile of sHLA-I molecules these experimental conditions, in which the α 1 and α 2 domains of sHLA-I molecules can bind to the TCR, whereas the α 3 Silver staining detected a 56 kDa band when sHLA-I molecules isolated from serum were electrophoresed under nondomain cannot bind to the CD8 α chain, sHLA-I molecules do not trigger apoptosis in target cells (Table 1) . In additional reducing/non-denaturing conditions (Fig. 1, lane 1) . This 
T cells was unaffected by preincubation with an anti-HLA-A3
sHLA-I triggers sFasL-mediated CD8 T cell apoptosis 199 Table 1 . Inhibition of apoptosis induced by sHLA-I molecules on PHA-activated CD8 ϩ T lymphocytes.
PHA-activated lymphocytes
Preincubation (1 h) sHLA-I molecules (4 µg/ml) Preincubation (1 h) Percent apoptotic cells
a Anti-CD8 α chain mAb (20 µg/ml). b Anti-HLA class I α 3 domain mAb (5 µg/ml). c Anti-HLA-A3 α 2 domain mAb (5 µg/ml). d Anti-HLA-A3 α 1 domain mAb (5 µg/ml). e 500 U/ml. α 1 domain mAb and was partially inhibited by preincubation an anti-human Fas neutralizing mAb before incubation with sHLA-I molecules. This finding reflects the inhibition of the with an anti-HLA-A3 α 2 domain mAb (Table 1 ). These findings suggest that, under our experimental conditions, sHLA-I-TCR binding of sFasL to PHA-activated Fas ϩ CD8 ϩ T cells by antihuman Fas neutralizing mAb (Fig. 5) . The apoptosis-inducing interaction in the absence of sHLA-I-CD8 interaction is unable to induce apoptosis in PHA-activated CD8 ϩ T cells.
activity of supernatants was abolished by preincubation with the an anti-human FasL mAb and by preincubation of Jurkat
Role of Fas-FasL interactions in the induction by sHLA-I
cells with an anti-human Fas neutralizing mAb (Fig. 5) . The molecules of apoptosis in CD8 ϩ T cells presence of sFasL molecules in supernatants is further supported by its detection by DDIA (0.86 Ϯ 0.24 µg/ml). SuperThe role of Fas-FasL interactions in sHLA-I-induced apoptosis of PHA-activated CD8 ϩ T cells was then investigated. The natants harvested from cultures of PHA-activated CD8 ϩ T cells in which the binding of the sHLA-I α 3 domain to CD8 α chain apoptosis-inducing activity of sHLA-I molecules was inhibited by preincubating with an anti-human Fas neutralizing mAb was blocked by preincubation with the appropriate mAb did not contain apoptosis-inducing activity (data not shown). These CD8 ϩ T cells which had acquired Fas (CD95) following a 72 h PHA activation (Fig. 4) . Additional experiments determined findings indicate that, in our experimental conditions, sHLA-I-TCR interaction in the absence of sHLA-I-CD8 interaction does whether the production of a soluble form of FasL (sFasL) (22, 36) was involved in the apoptosis-inducing activity of sHLA-I not induce sFasL secretion by PHA-activated CD8 ϩ T cells. Moreover, Fas mRNA was detected in CD8 ϩ T cells following molecules. Supernatants harvested from cultures of PHA-activated CD8 ϩ T cells incubated with sHLA-I molecules for 48 h PHA activation and FasL mRNA was detected in PHA-activated CD8 ϩ T cells following incubation with sHLA-I molecules induced apoptosis in Fas ϩ Jurkat cells (Fig. 5) . The apoptosisinducing activity was increased in supernatants incubated with (Fig. 6) . Taken together, these findings strongly suggest that sFasL is produced after the binding of sHLA-I antigens to PHAactivated CD8 ϩ T cells and mediates apoptosis in Fas ϩ CD8 ϩ T cells.
Discussion
Antigenic peptides are presented to the TCR in the context of the α 1 and α 2 domains of HLA class I antigens (37). During antigen presentation the α 3 domain binds to the α chain of CD8 of β 2 m. Moreover, apoptosis induction is inhibited by the pre-
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incubation of sHLA-I antigens with W6/32 mAb which blocks plantation (7). Increased serum levels of sFasL have been found in several clinical conditions like HIV-1 infection (63), the binding between HLA class I α 3 domain and CD8 α chain (40) as well as by preincubation of PHA-activated CD8 ϩ T large granular lymphocytic leukemia and NK cell lymphoma (22) , and graft versus host disease (64) . Elevated levels of cells with anti-CD8 α chain mAb. By contrast, apoptosis is not inhibited by the preincubation of sHLA-I antigens with an antifunctional sHLA-I and sFasL molecules have been detected in blood components and might play a role in the immunomodula-α 1 domain mAb, whereas it is partially inhibited by the preincubation with an anti-α 2 domain mAb. This latter finding tory effect of allogeneic transfusions (65) . Moreover, CD8 ϩ T lymphocytes undergoing apoptosis are present in lymph nodes suggests that the interaction between the α 2 domain of HLA class I antigens and the α chain of CD8 molecules might be also of HIV-1 ϩ patients (66) and in graft infiltrating mononuclear cells during acute rejection episodes (67,68). involved in apoptosis induction. This hypothesis is in agreement with previously published data showing that the residues of the Therefore, sHLA-I antigens secreted during immune system activation may bind to CD8 molecules on activated CD8 ϩ T α 2 domain which interact with the CD8 α chain are located outside from the region of interaction of the TCR and point down cells and induce sFasL secretion. Then, sFasL may act in an autocrine and/or paracrine way triggering apoptosis in towards a cavity composed of the α 1 -α 2 platform, the loops of the α 3 domain and β 2 m (41, 42) . The interaction between HLA activated CD8 ϩ CD95 ϩ T cells. If so, serum sHLA-I molecules may represent an important efferent arm of the network to class I antigens α 3 domain and CD8 α chain is required for the positive selection of CD8 ϩ T cells within the thymus and for T control the expansion of CD8 ϩ T lymphocytes and to downregulate immune responses. cell activation which follows the trimolecular ligation of TCR, antigen and MHC (38, 40, (43) (44) (45) (46) (47) . Our data suggest that an apoptotic signal may be delivered to CD8 ϩ T cells after CD8 Acknowledgements ligation by sHLA-I antigens. The cytoplasmic tail of CD8 α CD4 ϩ T cells (52) . Our data indicate that CD8 ligation by sHLA-I antigens induces the release of soluble FasL by PHA-activated References CD8 ϩ T lymphocytes. This conclusion is supported by several lines of evidence. First, FasL mRNA expression is up-regulated
